Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results | Zendy

Franck Morschhauser | Zendy; John P. Leonard | Zendy; Luis Fayad | Zendy; Bertrand Coiffier | Zendy; Marie-Odile Petillon | Zendy; Morton Coleman | Zendy; Stephen J. Schuster | Zendy; Martin J.S. Dyer | Zendy; Heather Horne | Zendy; Nick Teoh | Zendy; William A. Wegener | Zendy; David M. Goldenberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results

Author(s) -

Franck Morschhauser,

John P. Leonard,

Luis Fayad,

Bertrand Coiffier,

Marie-Odile Petillon,

Morton Coleman,

Stephen J. Schuster,

Martin J.S. Dyer,

Heather Horne,

Nick Teoh,

William A. Wegener,

David M. Goldenberg

Publication year - 2009

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2008.19.9117

Subject(s) - medicine , rituximab , lymphoma , gastroenterology , pharmacodynamics , follicular lymphoma , refractory (planetary science) , adverse effect , pharmacokinetics , physics , astrobiology

This is a multicenter phase I/II dose-finding study in relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating veltuzumab, a humanized anti-CD20 antibody with structure-function differences from chimeric rituximab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research